Key Takeaways Novo Nordisk and its partner reported phase II data for UBT251 in Chinese patients with type II diabetes.UBT251 showed up to a 2.16% HbA1c reduction and 9.8% weight loss, outperforming semaglutide and placebo.Novo Nordisk plans a global phase II in 2026, while its partner prepares for phase III trials in China.Novo Nordisk (NVO) and its partner, The United Laboratories International Holdings Limited ("TUL"), jointly announced top-line data from a phase II study in China, evaluating UBT251, a n ...

Corcept Therapeutics shares surge as lead drug gets FDA nod for ovarian cancer | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv A view shows the U.S. Food and Drug Administration (FDA) headquarters in Silver Spring, Maryland August 14, 2012. Picture taken August 14, 2012. REUTERS/Jason Reed Purchase Licensing Rights, opens new tab Companies Corcept Therapeutics Inc Follow Merck & Co Inc Follow U.S. Food and Drug Administration Foll ...

Novo Nordisk cuts Wegovy price in South Africa for a second time | Reuters Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. REUTERS/Hollie Adams Purchase Licensing Rights, opens new tab JOHANNESBURG, March 25 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tabis cutting South African prices of its weight-loss drug Wegovy for a second time since it la ...

Key Takeaways Bristol Myers expands Opdivo into new cHL settings, broadening reach across treatment lines.Label expansions and pipeline progress aim to offset generic pressure on legacy drugs like Revlimid.Oncology competition intensifies as Merck and Pfizer advance bispecifics and diversified cancer pipelines.Bristol Myers Squibb (BMY) recently won FDA and European Commission (EC) approvals for the label expansion of its blockbuster immuno-oncology (IO) drug Opdivo.The FDA approved Opdivo in combination wi ...

Every year in March, the Schwab U.S. Dividend Equity ETF (NYSEMKT: SCHD) reconstitutes and rebalances itself. This essentially means that it runs its strategic methodology from scratch and rebuilds its portfolio according to what's happening right now. Since this exchange-traded fund (ETF) is a favorite among dividend income investors, the annual reconstitution draws a lot of interest from investors. The ETF examines a broad universe of stocks to find those demonstrating strong balance sheet health, long ...

AstraZeneca PLC (NYSE:AZN) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 16, 2026, AstraZeneca PLC (NYSE:AZN) announced that Imfinzi, in combination with FLOT chemotherapy, has been approved in the European Union for treating adults with resectable early-stage and locally advanced gastric and gastroesophageal junction cancers. The company said the regimen includes treatment before and after surgery, followed by Imfinzi monotherapy, with the approval based on results from the Ph ...

DIJON, France – 25 mars 2026 (06.00 PM CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), the specialty pharmaceuticals company developing emergency medicines based on its proprietary ZENEO® needle-free auto-injector platform, notably ZEPIZURE® for the emergency treatment of epileptic seizures, today announces the appointment of Lionel Seltz as Chief Financial Officer. Before joining CROSSJECT, Lionel Seltz served as CFO North Europe at Antech Diagnostics, where he led finance across several countri ...

It is important to acknowledge that while other factors will have contributed to this drop (such as regulatory delays, pricing and reimbursement negotiations, or supply chain constraints), the trend seen is an early signal of the impact that the introduction of IRP in the US has had on European markets. Based on the MFN policy framework and reference baskets, the lowest-priced markets are used as a reference point for US pricing. Consequentially, there is a structural disincentive to launch early in countri ...

UCB has chosen Georgia as the home for its new biologics manufacturing facility, cementing its legacy in the state and marking the company’s latest expansion effort in the key US market. The $2bn, 460,000 ft², digital-first site, located in Gwinnett County’s Rowen Development, will be the “cornerstone” of UCB’s global biologics manufacturing infrastructure – operating 24/7 once in action to supply the US market. When the facility is up and running, it will employ around 330 skilled staff, while generati ...

A month has gone by since the last earnings report for Axsome Therapeutics (AXSM) . Shares have lost about 6.6% in that time frame, underperforming the S&P 500.But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Axsome due for a breakout? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent catalysts for Axsome Therapeutics, Inc. before we dive into how investors and analysts hav ...